JMJosé Luis Millán

José Luis Millán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José Luis Millán has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TNAP and PHOSPHO1 Function Synergistically to Afford Critical Control Over the Mineralization of the Postnatal Murine Skeleton

    by Lucie E. Bourne, Aikta Sharma, Scott Dillon, Jacob Keen, Soher N. Jayash, Natalie Crump, Lucinda A.E. Evans, Maya Karmali, Worachet Promruk, Claire E. Clarkin, et al.

    Biomineralization is essential for skeletal integrity, yet the synergistic roles of tissue non‐specific alkaline phosphatase (TNAP) and PHOSPHO1 in postnatal bone remain unclear. We generated a novel murine model with Prx1 ‐driven deletion of Alpl ( Alpl Prx1/Prx1 ) on a global Phospho1 −/− background, circumventing the perinatal lethality associated with dual global deletion and premature death of Alpl global knockouts. Multi‐modal spatial phenotyping of the limbs revealed that mice lacking both TNAP and PHOSPHO1 exhibit distinct mineralization defects and altered anatomical structures at postnatal day 1 (PN1) and 3‐weeks of age. Although viable, these mice did not thrive due to reduced size; thus further investigations were conducted on mice with heterozygous deletion of TNAP ( Alpl wt/Prx1 ;Phospho1 −/− ). Although smaller than wild‐types at PN1 and 3 weeks old, these mice preserved gross limb structure and the single, functioning Alpl allele rescued biomineralization loss following dual phosphatase deletion. In 6‐week animals, compromised epiphyses and metaphyses were only observed in Alpl Prx1/Prx1 animals. Conversely, diaphyseal geometry and porosity were altered by Phospho1 deletion, compounded in Alpl wt/Prx1 ;Phospho1 −/‒ mice, and linked to alterations in collagen configuration, matrix mineralization, and growth plate deformities. Together, our findings support a mechanistic framework for TNAP and PHOSPHO1 in permissive biomineralization, providing critical insights into this fundamental process.


  • Open Access

    PHOSPHO1 deficiency delays osteogenic differentiation of osteoblasts, impairing mineralization and altering the protein composition of matrix vesicles

    by Luiz Henrique da Silva Andrilli, Cintia Kazuko Tokuhara, Larwsk Hayann Silva, Angie Puelles, Colin Farquharson, Ana Paula Ramos, Jose Luis Millán, Flavia Amadeu de Oliveira, Pietro Ciancaglini

    Matrix vesicles (MVs), a specialized class of extracellular vesicles, play a central role in skeletal mineralization. Phosphoethanolamine/phosphocholine phosphatase 1 (PHOSPHO1) generates inorganic phosphate (Pi) within the MV lumen and is considered essential for the initiation of mineralization. This study investigated the role of PHOSPHO1 in osteoblast differentiation and MV biology using primary calvariae osteoblasts from 6-day-old wild-type (WT) and Phospho1-/- mice. Cells were cultured under osteogenic conditions for 14 and 21 days, followed by analyses of cell viability, mineralization, gene expression, MV biophysical properties, and proteomic analyses. Phospho1-/- osteoblasts exhibited threefold higher mitochondrial activity than WT cells. Mineral deposition was detected only in WT cultures at day 21, indicating impaired mineralization in the absence of PHOSPHO1. Gene expression analysis revealed increased Alpl and Smpd3, and decreased Enpp1 expression in Phospho1-/- osteoblasts. Consistent with these findings, alkaline phosphatase (ALP) activity in MVs increased 7.5-fold between days 14 and 21 in both genotypes. Atomic force microscopy of MVs derived from Phospho1-/- osteoblasts exhibited a 6.5- and 2.1-fold reduction in vesicle volume and surface roughness, respectively, compared with WT MVs. Proteomic analysis revealed reduced tissue non-specific alkaline phosphatase (TNAP) at day 14, followed by increased TNAP levels at day 21, accompanied by decreased collagen XII and collagen VI content in Phospho1-/- MV preparations. Collectively, these findings indicate that cellular adaptation is insufficient to restore mineralization in the absence of PHOSPHO1. Instead, PHOSPHO1 appears to play a critical role in establishing the molecular and biophysical properties of MVs necessary for mineral nucleation and propagation.

  • Glycerol-driven TNAP activation in thermogenesis and mineralization

    by Mohammed Faiz Hussain, Shreya S. Krishnan, Brittany L. Carroll, Bozena Samborska, Aisha Mousa, Alice Williamson, Maria Delgado-Martin, Bindu Y. Srinivasu, Jakub Bunk, Janane F. Rahbani, et al.

    Tissue-nonspecific alkaline phosphatase (TNAP) promotes skeletal mineralization by hydrolysing pyrophosphate1 and has been linked to uncoupling protein 1 (UCP1)-independent adipocyte thermogenesis through the futile creatine cycle through phosphocreatine hydrolysis2,3. Despite TNAP’s broad physiological roles, endogenous regulators of its activity have not been defined. Furthermore, the activation mechanism of UCP1-independent thermogenesis has remained unresolved. Here we identify glycerol as an allosteric activator of TNAP. Glycerol binds to a surface pocket distal to the active site, which we term the glycerol pocket, to enhance TNAP activity. Using biophysical, structural, bioenergetic and physiological approaches, we show that the glycerol pocket is required for TNAP-driven thermogenesis. Through this mechanism, TNAP activates the futile creatine cycle, acting as a physiological complement to UCP1. The glycerol pocket is likewise required for optimal osteoblast-regulated mineralization. Human missense variants in this site reduce TNAP-dependent mineralization in vitro and are associated with lower alkaline phosphatase activity and bone mineral density, providing genetic evidence that its disruption impairs skeletal physiology.


  • Open Access

    Effects of comorbid chronic kidney disease on late-onset hypophosphatasia mice under treatment with asfotase alfa

    by Cintia Tokuhara, Flavia Amadeu de Oliveira, Sonoko Narisawa, Elis J Lira dos Santos, Brian L Foster, Jose Luis Millan

    Hypophosphatasia (HPP) is a rare bone disorder caused by loss-of-function mutations in the ALPL gene, leading to deficient tissue-nonspecific alkaline phosphatase (TNAP) activity and impaired skeletal/dental mineralization. Asfotase alfa (AA), the only FDA-approved therapy, improves survival and skeletal/dental mineralization. Because of its mineral-binding properties, AA also binds to sites of ectopic calcification, including vasculature. Overexpression of TNAP in either the vascular media or intima has been shown to induce severe calcification. Here, we examined what might occur if a disease that features medial artery calcification, such as CKD-mineral and bone disorder (CKD-MBD), were to develop in a subject with HPP undergoing AA treatment. Two-month-old AlplPrx1/− (HPP) or Alplflox/− (non-HPP control) mice were treated with s.c. AA injections (8.2 mg/kg, 3×/week) for 4 mo. After 3 mo of treatment, CKD was induced via a 0.2% adenine and 1.8% phosphorus diet. Mice were euthanized at 6 mo of age, and skeletal, renal, cardiac, and vascular tissues were analyzed. Alkaline phosphatase levels slightly increased with AA but significantly increased after inducing CKD in control and HPP female mice. In males, ALP activity was elevated in the AA and AA+CKD cohorts. Micro-CT analysis showed improved bone parameters in HPP under AA treatment. However, the improvements were dampened when CKD was induced, compared to non-CKD Alplflox/−. Immunohistochemistry of the kidney revealed increased TNAP immunolocalization in the AA+CKD cohort, in both females and males. Ectopic renal and vascular calcification was observed in the AA+CKD group. Gene expression profiling in the kidney revealed that AA treatment modulates the immune and mineral metabolism pathways, while CKD superimposition induces a shift toward pro-inflammatory and pro-fibrotic responses, compromising renal and skeletal homeostasis. These findings underscore the importance of carefully evaluating HPP patients under treatment with mineral-targeted TNAP at risk of developing comorbid conditions associated with ectopic calcification.

  • Open Access

    Mineral‐targeted alkaline phosphatase improves bone graft‐mediated alveolar bone defect healing in mice

    by Kedith Sawangsri, Aonjittra Phanrungsuwan, Binnaz Leblebicioglu, José Luis Millán, Brian L. Foster

    Background: Alveolar bone loss challenges tooth retention and implant placement. Freeze‐dried bone allograft (FDBA) is widely used for alveolar ridge preservation but has limitations in resorption rate and healing time. In this proof‐of‐concept study, we tested whether pro‐mineralization enzyme, tissue‐nonspecific alkaline phosphatase (TNAP) enhances bone healing. Methods: Seven‐week‐old mice ( n = 4‐6/group; equal numbers of males and females) underwent maxillary molar extraction and standardized alveolar defect creation. Mice were assigned to sham, FDBA with saline (BGS) or FDBA with mineral‐targeted TNAP‐Fc‐D 10 (BGT). Healing was assessed using microcomputed tomography (micro‐CT), serum alkaline phosphatase (ALP) levels, histology, and immunohistochemistry, between 14‐ and 60‐days post‐procedure (dpp). Intergroup comparisons were analyzed by one‐way ANOVA and post‐hoc Tukey test ( α = 0.05) Results: At 14 dpp, the BGT group demonstrated significantly greater bone volume fraction (BV/TV) and bone mineral density (BMD) compared with BGS ( p < 0.01, p < 0.05) and sham groups ( p < 0.001). Alveolar bone volume was greater than sham ( p < 0.001). Alveolar bone dimension (height and width) was significantly more stable in the BGT group ( p < 0.05). Although BV/TV at 60 dpp showed no significant differences, BGT maintained higher BMD and alveolar bone width stability ( p < 0.01). Histological and immunohistochemical analyses revealed increased new bone formation and greater bone marker expression in the short‐term BGT group ( p < 0.05). No changes in serum ALP levels were detected. Conclusions: TNAP‐Fc‐D 10 with FDBA significantly enhances early alveolar bone healing and dimensional stability. While long‐term volumetric gains were not observed, sustained improvements in mineral density and ridge preservation support TNAP as a promising biologic for alveolar ridge preservation. Plain language summary: When people lose teeth, keeping enough bone in the jaw is critical for future treatments like dental implants. A common material used to rebuild bone is called freeze‐dried bone allograft (FDBA), but it does not always heal quickly or completely. In this study, we tested whether adding a special enzyme called TNAP, which helps build bones naturally, could make FDBA work better. After extracting teeth and creating bone defects in mice, we compared healing between three groups: control (sham), FDBA + saline, and FDBA + engineered TNAP‐Fc‐D 10 . After 2 weeks, the group that received FDBA+TNAP‐Fc‐D 10 showed more new bone formation and better preservation of the size of the jawbone. Even after 2 months, their bone remained denser and more stable compared with the other groups. Importantly, we found no signs of unwanted side effects in the blood. These results suggest that adding TNAP‐Fc‐D 10  could make bone grafts more effective early on, helping preserve jaw structure better over time. More research is needed to fine‐tune the treatment and see how well it works in humans.


  • Open Access

    N-linked glycosylation plays an essential role in the stability and function of tissue-nonspecific alkaline phosphatase

    by Diana Atanasova, Ali Saad Kusay, Lavanya Moparthi, Stefan Koch, Mathias Haarhaus, Sonoko Narisawa, José Luis Millán, Eva Landberg, Per Magnusson


  • Open Access

    Alpl ablation in dental epithelium disrupts ameloblasts and incisor enamel mineralization in male mice

    by Fatma F Mohamed, Shifa Shahid, José L Millán, Brian L Foster

    Tissue-nonspecific alkaline phosphatase (gene: ALPL; protein: TNAP) is a mineralization-associated enzyme that catalyzes several physiological substrates and is widely expressed in skeletal and nonskeletal tissues indicating diverse physiological actions. Loss-of-function mutations in ALPL cause hypophosphatasia (HPP), an inherited skeletal dysplasia featuring rickets and osteomalacia. Hypophosphatasia is also associated with dentoalveolar abnormalities, including dentin defects and acellular cementum hypoplasia, resulting in premature tooth loss. Some reports indicate HPP causes enamel defects. We conditionally ablated Alpl in enamel organ by crossing Krt14Cre and Alplfl/fl mice to generate Krt14Cre;Alplfl/fl conditional KO (cKO) mice. Control (CTR) and cKO mice were analyzed at 14 and 60 d postnatal using micro-CT, histology, scanning electron microscopy, and an ex vivo caries induction model. In situ hybridization of the incisor revealed Alpl mRNA was expressed in stratum intermedium and maturation stage ameloblasts, but not preameloblasts or secretory stage ameloblasts. Compared to CTR, cKO mice showed no differences in body weight, circulating alkaline phosphatase, or cranial and appendicular bone parameters. By gross observation, cKO incisors showed discoloration, surface irregularities, and blunted tips; however, these alterations were evident in only male cKO mice. Micro-CT analysis indicated enamel hypomineralization in male cKO vs CTR incisors. Scanning electron microscopy showed intact rod-interrod pattern but less mineralized, thinner crystals in male cKO vs CTR incisors. Histology of male cKO incisors revealed impaired prematuration stage ameloblasts due to ameloblast/enamel detachment near the enamel–dentin junction, aberrant proliferating cell nuclear antigen immunostaining, and disorganized multicellular layers. Immunohistochemistry revealed disrupted enamel matrix proteins in cKO incisors. Conditional Alpl ablation in enamel epithelium revealed enamel phenotypes and suggests potential role(s) in maintaining ameloblast integrity, proper initial enamel matrix secretion, and enamel mineralization. Collectively, these findings confirm a role for TNAP in amelogenesis and point to direct effects of HPP on enamel formation, improving our understanding of amelogenesis.


  • Open Access

    Genetic reduction or deletion of osteopontin in osteomalacic Hyp mice fails to ameliorate dentoalveolar defects

    by Aonjittra Phanrungsuwan, Bella Donnelly, Jinju Kim, Jack Sweet, Flavia Amadeu de Oliveira, Do-Gyoon Kim, Eva S Liu, José Luis Millán, Marc D McKee, Brian L Foster

    X-linked hypophosphatemia (XLH) is caused by inactivating mutations in PHEX, leading to disturbed mineral metabolism, rickets, and osteomalacia. Dentoalveolar defects affecting dentin, cementum, and alveolar bone, contribute to dental abscesses and periodontal breakdown. Limited efficacy of current therapies for ameliorating XLH-associated dentoalveolar effects suggests mechanisms of disease that remain unchecked. Increased production and abnormal distribution of osteopontin (OPN) is thought to contribute to XLH-associated mineralization defects. Osteopontin is a secreted phosphoprotein and mineralization inhibitor, and a substrate of PHEX. To investigate the potential role of OPN in the pathology of XLH-associated dentoalveolar defects, a genetic approach was used to ablate or diminish Spp1/OPN in the Hyp mouse model of XLH. One or both Spp1 alleles in Hyp mice were deleted and tissues were analyzed at 60 d postnatally (dpn). Micro-CT showed no differences in volumes or densities of dentin and alveolar bone in Hyp mice lacking one or both Spp1 alleles, as compared to control Hyp mice. Histological assessment showed no improvements in cementum or periodontal ligament attachment, and dynamic mechanical analysis revealed no normalization of periodontal mechanical properties. While OPN may play a role in regulating dentoalveolar mineralization, diminishing OPN alone was not sufficient to substantially ameliorate XLH-associated defects.


  • Open Access

    TNAP dephosphorylates phosphocholine and phosphoethanolamine and participates in triglyceride transport from the liver to the bloodstream

    by Eva Drevet Mulard, Iliass Imam, Pierre-Damien Coureux, Anne Briolay, Laurence Bessueille, Antoine Tarby, Stéphane Balayssac, Sonoko Narisawa, Felix Lecornu, Véronique Gilard, et al.

    Tissue-nonspecific alkaline phosphatase (TNAP) is primarily known for its role in skeletal mineralization, through the hydrolysis of inorganic pyrophosphate (PPi). Here we demonstrate that TNAP-knockout mice exhibit liver steatosis and reduced serum triglyceride levels, mirroring the effects of choline deficiency, which impairs phosphatidylcholine synthesis, an essential component of VLDL. In fasting WT mice, TNAP inhibition via SBI-425 administration decreases choline levels in blood and liver. Incubating mouse or human serum with SBI-425 inhibits the dephosphorylation of phosphocholine and phosphoethanolamine, an alternative substrate for hepatic phosphatidylcholine synthesis. In hepatocytes, TNAP inhibition impedes proliferation when the medium is supplemented with phosphocholine instead of choline. Recombinant TNAP hydrolyzes phosphocholine and phosphoethanolamine with similar efficiency than PPi. X-ray diffraction and cryo-EM identified the residues in TNAP’s active site interacting with phosphocholine, PPi and the TNAP inhibitor. In summary, TNAP is the phosphatase enabling cellular choline uptake during fasting, participating in hepatic lipid metabolism.


  • Open Access

    Proof-of-principle for enhanced dentoalveolar mineralization using exogenous tissue-nonspecific alkaline phosphatase in the Hyp mouse model of X-linked hypophosphatemia

    by Aonjittra Phanrungsuwan, Bella Donnelly, Fatma F Mohamed, Kedith Sawangsri, Karli Belgya, Tamara N Kolli, Jinju Kim, Do-Gyoon Kim, Flavia Amadeu de Oliveira, Eva S Liu, et al.

    X-linked hypophosphatemia (XLH) is caused by mutations in the PHEX gene, which leads to increased levels of fibroblast growth factor 23 and hypophosphatemia, contributing to rickets, osteomalacia, and dentoalveolar defects, including severe dentin hypomineralization, thin cementum, and alveolar bone osteomalacia. Current XLH treatment options appear to have limited efficacy on dentoalveolar tissues, suggesting underlying disease mechanisms that remain unchecked. Increased production of inorganic pyrophosphate (PPi) and osteopontin (OPN), both mineralization inhibitors, has been posited to contribute to mineralization defects in XLH. The enzyme, tissue-nonspecific alkaline phosphatase (TNAP) reduces PPi levels via hydrolysis and inactivates OPN by dephosphorylation. Our previous study showed improved alveolar bone socket healing in Hyp mice administered mineralized tissue-targeted TNAP (TNAP-Fc-D10). We hypothesized that increased TNAP would partially ameliorate developmental mineralization defects in XLH by dually reducing PPi levels and dephosphorylating and inactivating OPN. In a proof-of-principle study to investigate pathological mechanisms, we delivered systemic (subcutaneous injection) and local (submucosal injection to mandibles) TNAP-Fc-D10 injections to the Hyp mutant mouse model of XLH from 7 to 60 d postnatal (dpn). While systemic delivery was ineffective at improving dentin or bone properties, micro-CT and histology analyses demonstrated that local delivery of TNAP-Fc-D10 increased dentin thickness, root length, alveolar bone volume, alveolar bone proper (ABP) volume and density, PDL attachment, and acellular cementum thickness, compared to control Hyp mice receiving a sham injection. Dynamic mechanical testing confirmed partially improved mechanical properties in locally treated vs untreated Hyp mice, suggesting incompletely improved periodontal function. Quantitative PCR revealed increased Dspp expression in molars of treated Hyp mice. In conclusion, we found TNAP administration reduced dentoalveolar defects in Hyp mice when delivered locally into dentoalveolar structures, proof-of-principle pointing to a pathological contribution by PPi and/or OPN and highlighting a promising adjunctive approach considering limitations of current treatment modalities.